$CHE

Chemed (NYSE:CHE) Exceeds Q2 CY2026 Expectations

Chemed Corp (NYSE:CHE) reported Q2 CY2026 revenue of $673.3 million, up 8.8% year on year and 1.2% above Wall Street estimates, and non-GAAP EPS of $6.06, 8.2% above consensus. Analysts expect revenue growth of about 7% and full-year EPS to rise from $23.40 to $25.61.

Original reporting
Published Jul 28, 2026, 9:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 28, 2026, 9:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Chemed (NYSE:CHE) Exceeds Q2 CY2026 Expectations — source image
Decision brief

The 30-second read

$CHEBullishMed
01

Why it matters

Q2 CY2026 results beat consensus on revenue and non-GAAP EPS, with adjusted operating margin improving year over year, which can influence near-term estimate revisions and positioning.

02

Market read

Traders can reassess near-term expectations given the quantified beat versus Wall Street estimates and the stated forward EPS growth range.

03

What to watch

No detail is provided on cash flow quality, hospice utilization trends, or Roto-Rooter demand drivers, which could determine whether the beat leads to estimate upgrades.

Relevance 7/10Novelty 6/10Timing: after-hours/late-day following Q2 CY2026 results release

Background

Chemed operates VITAS hospice care and Roto-Rooter plumbing and water restoration services, and reports billable days as an operating metric.

Company-level read

Ticker impact

$CHEBullishMedium confidence
Context

Chemed reported Q2 CY2026 revenue of $673.3M (+8.8% YoY) and non-GAAP EPS $6.06, both beating consensus estimates.

Expected impact

Likely near-term positive bias versus peers, with follow-through dependent on whether the beat translates into upward revisions.

Evidence & confidence

The article provides specific beat metrics (revenue +1.2% vs estimates, EPS +8.2% vs estimates) and cites a forward EPS growth expectation, but it does not include management guidance or a new revision event.

Market effects

Hospice and household services demand signals remain supportive, but the article does not provide sector-wide guidance changes.

No regional macro or policy drivers are discussed.

No global supply chain or international demand factors are mentioned.

Counterpoint

The article notes weaker longer-term profitability trends (margin down over five years), so the beat may reflect temporary efficiency rather than durable re-acceleration.

Key entities

  • Chemed Corporation

    Healthcare services company with VITAS hospice and Roto-Rooter services; reported Q2 CY2026 results.

  • VITAS

    Chemed hospice care segment referenced in the company overview.

  • Roto-Rooter

    Chemed plumbing and water restoration segment referenced in the company overview.

Related articles

$CHEMed

CHEMED CORP (CHE): Results of Operations and Financial Condition

CHEMED CORP (CHE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99 2 che-20260728xex99.htm EX-99 Exhibit 99 CONTACT: Michael D. Witzeman (513) 762- 6714  Chemed Reports Second-Quarter 2026 Results  Full-Year Guidance Increased Due Mainly to VITAS Outperformance   CINCINNATI, July 28, 2026— Chemed Corporation (Chemed) (NYSE: CHE ), whic

$CHEMed

Roto-Rooter Buys Franchise Territory in Corpus Christi, Rio Grande Valley, and Beaumont, Texas

Chemed Corp. (NYSE: CHE) said its wholly owned Roto-Rooter unit acquired an independent Roto-Rooter franchise covering 21 south Texas counties, including Corpus Christi, McAllen, Laredo and Brownsville, for about $12.0 million. The company operates Roto-Rooter plumbing and drain cleaning services and VITAS hospice care. The release includes standard forward-looking statement cautions.

$BWINMed

Michael Dell Just Made a $7.7 Billion Bet on This Insurance Stock

Michael Dell is acquiring Baldwin & Co. (BWIN) for $7.7B. Baldwin reported Q2 revenue of $492.9M (+30% YoY), adjusted net income of $68.5M, and adjusted EBITDA of $116.7M (+37%). Management guided Q3 revenue to $485M-$495M and full-year revenue to $2.01B-$2.05B. Analysts have mixed targets, with a consensus 'Moderate Buy' and average target of $33.

$AMZNMedAI 8/10

Should You Buy Amazon Stock For The Demand AWS Cannot Yet Serve?

Amazon.com (AMZN) stock is down 13% from its 52-week high, despite AWS's 36.7% YOY revenue growth in Q2 2026. AWS's backlog of committed contracts reached $496 billion, with demand outpacing capacity. AWS's operating margin improved 520 basis points YOY, excluding energy contract gains. Management attributes growth to AI workloads and efficient capacity use.

$ASMLMedAI 8/10

Weakness Is an Opportunity for Long-Term ASML Stock Investors

ASML's High-NA technology is gaining traction among chipmakers like Samsung, Intel, and TSMC, crucial for its long-term outlook. Q2 earnings beat estimates with €7.59 EPS and €9.33B revenue. ASML raised full-year 2026 sales guidance to €43B-€45B. Analysts have a consensus 'Hold' rating, with a mean price target of $2,350.75, implying 56% upside.